{"id":2903,"date":"2023-12-08T01:31:04","date_gmt":"2023-12-08T01:31:04","guid":{"rendered":"https:\/\/economicherald.net\/?p=2903"},"modified":"2023-12-08T01:31:04","modified_gmt":"2023-12-08T01:31:04","slug":"asx-health-stocks-oncosil-advances-pancreatic-cancer-device-to-greece-its-third-potential-market-in-europe","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=2903","title":{"rendered":"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe"},"content":{"rendered":"<p>Oncosil says first two patient treatments using OncoSil device happened in Greece<br \/>\nNova Eye says Medicare reimbursement decision in the US delayed from December to January<\/p>\n<p>\u00a0<\/p>\n<h2>Oncosil\u2019s device used in Greece hospital<\/h2>\n<p>The medical device company focusing on pancreatic cancer,<strong><a href=\"https:\/\/stockhead.com.au\/company\/oncosil-medical-osl\/\"> Oncosil Medical (ASX:OSL)<\/a>,<\/strong> jumped 12% this morning after an update on its <strong>OncoSil device<\/strong>.<\/p>\n<p>Oncosil said the first initial commercial treatments involving the OncoSil device in Greece have just commenced at a renowned hospital in Athens. The first two patient treatments using the device occurred yesterday at the Agios Savvas Hospital, located in Athens.<\/p>\n<p>These treatments see Greece become the third European country \u2013 after Italy and Spain \u2013 where commercial treatments utilising the OncoSil device have been completed.<\/p>\n<p>As these treatments are commercial rather than clinical trial related, they additionally represent a clear positive signal for OncoSil\u2019s long\u2010term sustainability, says Oncosil.<\/p>\n<p>Oncosil also says this is another milestone in the commercialisation strategy for the device, which is intended for the treatment of <strong>locally advanced unresectable pancreatic cancer<\/strong>, in combination with gemcitabine\u2010based chemotherapy.<\/p>\n<p>\u201cIt\u2019s good to see the continued progress being made in our concerted efforts to commercialise the OncoSil device,\u201d said Oncosil\u2019s CEO, Nigel Lange.<\/p>\n<p>\u201cThe just\u2010completed initial commercial treatments in Greece at the Agios Savvas Hospital means that our innovative OncoSil device has now been utilised in commercial treatments in three European countries \u2013 and we remain confident that other countries across Western Europe will join this list.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Nova Eye gets temporary reprieve on US Medicare decision<\/h2>\n<p>Meanwhile, <strong><a href=\"https:\/\/stockhead.com.au\/company\/nova-eye-medical-eye\/\">Nova Eye (ASX:EYE)<\/a><\/strong> rose almost 9% after announcing that five <strong>MACs (Medicare Administrative Contractors)<\/strong> have deferred the proposed USA reimbursement changes from 23 December 2023, to January 29, 2024.<\/p>\n<p>The deferral by all five MACs is a positive outcome for the near-term sales of the company\u2019s iTrack portfolio of canaloplasty devices, which continue to be strong since the US launch of iTrack Advance in May.<\/p>\n<p>As a quick background, in November EYE reported that four additional MACs have proposed LCD (local coverage determination) changes on Medicare reimbursement of\u00a0minimally invasive glaucoma surgery (MIGS)\u00a0procedures in the US.<\/p>\n<p>This would have hit Nova Eye particularly hard, as \u201capproximately 40% of the company\u2019s global revenues are derived from health care facilities located in the 38 states covered by these four MACs,\u201d according to a release from EYE.<\/p>\n<p>But a fortnight later, EYE advised that the final draft of the LCD, issued by the <strong>US National Government Services (NGS)<\/strong>, has been deferred from December 23 to March 23, 2024.<\/p>\n<p>The NGS administers insurance reimbursement claims of healthcare facilities in the states of New York, Connecticut, Rhode Island, Massachusetts, Vermont, New Hampshire, Maine, Minnesota, Illinois, and Wisconsin.<\/p>\n<p>NGS said the the deferral is to \u201callow more time to make decisions regarding comments received\u201d.<\/p>\n<p>Following today\u2019s announcement, reimbursement coverage of canaloplasty surgeries in the 38 US states covered by the five MACs beyond January 29, 2024, will depend on whether the proposed LCDs are implemented.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-oncosil-advances-pancreatic-cancer-device-to-greece-its-third-potential-market-in-europe\/\">ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Oncosil says first two patient treatments using OncoSil device happened in Greece Nova Eye says Medicare reimbursement decision in the US delayed from December to <a href=\"https:\/\/economicherald.net\/?p=2903\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":2904,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=2903\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Oncosil says first two patient treatments using OncoSil device happened in Greece Nova Eye says Medicare reimbursement decision in the US delayed from December to [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=2903\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-08T01:31:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe\",\"datePublished\":\"2023-12-08T01:31:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903\"},\"wordCount\":526,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2903#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=2903\",\"name\":\"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg\",\"datePublished\":\"2023-12-08T01:31:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2903\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2903#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=2903","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe - Economic Herald","og_description":"Oncosil says first two patient treatments using OncoSil device happened in Greece Nova Eye says Medicare reimbursement decision in the US delayed from December to [more...]","og_url":"https:\/\/economicherald.net\/?p=2903","og_site_name":"Economic Herald","article_published_time":"2023-12-08T01:31:04+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=2903#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=2903"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe","datePublished":"2023-12-08T01:31:04+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=2903"},"wordCount":526,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=2903#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=2903#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=2903","url":"https:\/\/economicherald.net\/?p=2903","name":"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=2903#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=2903#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg","datePublished":"2023-12-08T01:31:04+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=2903#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=2903"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=2903#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/12\/Oncosil-says-first-two-patient-treatments-using-OncoSil-device-happened-in-Greece.-Picture-Getty-buwEbo.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=2903#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2903"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/2904"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}